0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Translational Science With Clinical Promise |

Recombinant T-Cell Receptor Ligands in the Treatment of Uveitis

Marco A. Zarbin, MD, PhD
JAMA Ophthalmol. 2013;131(3):399-400. doi:10.1001/jamaophthalmol.2013.111.
Text Size: A A A
Published online

Extract

Uveitis is a major cause of blindness worldwide. Typically, topical and/or systemic corticosteroids are used for the initial treatment of uveitis, but local and systemic adverse effects (eg, cataract, glaucoma, adrenal suppression, and hyperglycemia) may limit long-term use. Alternative immunomodulatory agents include antimetabolites (eg, azathioprine, methotrexate, and mycophenolate mofetil), alkylating agents (eg, cyclophosphamide and chlorambucil), T-cell inhibitors (eg, cyclosporine and tacrolimus), and cytokine inhibitors (eg, infliximab, which blocks tumor necrosis factor-α, and daclizumab, which blocks interleukin-2R). These agents are quite effective, but they too can be associated with serious adverse effects (eg, pancytopenia, hemorrhagic cystitis, opportunistic infections, and lymphoma).

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();